This Article Full Text Full Text (PDF) All Versions of this Article: 91/3/1181    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hammarstedt, A. Articles by Smith, U. Search for Related Content PubMed PubMed Citation Articles by Hammarstedt, A. Articles by Smith, U. Related Collections Metabolism

Visfatin Is an Adipokine, But It Is Not Regulated by Thiazolidinediones

Lundberg Laboratory for Diabetes Research (A.H., V.R.S., S.G., P.-A.J., U.S.), Department of Internal Medicine, Sahlgrenska Academy, Goteborg University, Goteborg, Sweden; and Department of Medicine (J.P., M.L.), University of Kuopio, SE-413 45 Kuopio, Finland

Address all correspondence and requests for reprints to: Dr. Ann Hammarstedt, Lundberg Laboratory for Diabetes Research, Department of Internal Medicine, Sahlgrenska University Hospital, SE-413 45 Goteborg, Sweden. E-mail: ann.hammarstedt{at}medic.gu.se.

Context: Visfatin was recently reported to be expressed in human adipose tissue and to exert insulin-mimicking effects.

Objective: The objective of this study was to examine whether visfatin is a true adipokine and is expressed in isolated fat cells. We also examined whether visfatin is regulated by thiazolidinediones and, thus, can contribute to the ability of these agents to improve insulin sensitivity.

Design: This was an open-labeled drug therapy trial.

Setting: This study was performed at a university hospital.

Patients: Seven newly diagnosed and previously untreated type 2 diabetic patients and six healthy individuals with reduced insulin sensitivity participated in the study.

Intervention: Pioglitazone therapy (30–45 mg/d) was given for 3–4 wk.

Main Outcome Measures: Serum and adipose tissue mRNA levels of visfatin and adiponectin were the main outcome measures.

Results: Visfatin mRNA is expressed in both adipose tissue and isolated adipocytes. Treatment with thiazolidinediones for 3–4 wk did not alter the gene expression or circulating levels of visfatin in either nondiabetic or the diabetic individuals, whereas adiponectin increased significantly.

Conclusion: The present study shows that visfatin is a true adipokine, but it is not regulated by TZD and, thus, is unlikely to contribute to the insulin-sensitizing actions of these drugs.

This article has been cited by other articles:

				P. G. McTernan and S. Kumar Retinol Binding Protein 4 and Pathogenesis of Diabetes J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2430 - 2432. [Full Text] [PDF]

				V. Varma, A. Yao-Borengasser, N. Rasouli, A. M. Bodles, B. Phanavanh, M.-J. Lee, T. Starks, L. M. Kern, H. J. Spencer III, R. E. McGehee Jr., et al. Human Visfatin Expression: Relationship to Insulin Sensitivity, Intramyocellular Lipids, and Inflammation J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 666 - 672. [Abstract] [Full Text] [PDF]

				B. K. Tan, J. Chen, J. E. Digby, S. D. Keay, C. R. Kennedy, and H. S. Randeva Increased Visfatin Messenger Ribonucleic Acid and Protein Levels in Adipose Tissue and Adipocytes in Women with Polycystic Ovary Syndrome: Parallel Increase in Plasma Visfatin J. Clin. Endocrinol. Metab., December 1, 2006; 91(12): 5022 - 5028. [Abstract] [Full Text] [PDF]

				D. G. Haider, F. Mittermayer, G. Schaller, M. Artwohl, S. M. Baumgartner-Parzer, G. Prager, M. Roden, and M. Wolzt Free fatty acids normalize a rosiglitazone-induced visfatin release Am J Physiol Endocrinol Metab, November 1, 2006; 291(5): E885 - E890. [Abstract] [Full Text] [PDF]

				C. Pagano, C. Pilon, M. Olivieri, P. Mason, R. Fabris, R. Serra, G. Milan, M. Rossato, G. Federspil, and R. Vettor Reduced Plasma Visfatin/Pre-B Cell Colony-Enhancing Factor in Obesity Is Not Related to Insulin Resistance in Humans J. Clin. Endocrinol. Metab., August 1, 2006; 91(8): 3165 - 3170. [Abstract] [Full Text] [PDF]